News

bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes

  • SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technology reports record Q1 2024 revenue driven by accelerating sales of lung cancer diagnostic CyPath Lung.
    05/15/2024

bioAffinity Technologies News Update

  • SAN ANTONIO--(BUSINESS WIRE)-- #ATS--bioAffinity reports ramp in sales of CyPath® Lung, expanded sales team, new Patient Coach and upcoming presentation at American Thoracic Society.
    05/02/2024
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

bioAffinity Technologies, Inc. (BIAF) can sell. Click on Rating Page for detail.

The price of bioAffinity Technologies, Inc. (BIAF) is 2.26 and it was updated on 2024-05-18 07:01:13.

Currently bioAffinity Technologies, Inc. (BIAF) is in undervalued.

News
    
News

bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth

  • SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies is developing diagnostics based on its proprietary platform for use with BAL fluid to detect lung cancer and to detect COPD.
    Wed, Apr. 24, 2024

bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening

  • SAN ANTONIO--(BUSINESS WIRE)-- #ACS--bioAffinity Technologies and the American Cancer Society are expanding their campaign to raise funds for lung cancer screening.
    Tue, Apr. 09, 2024

Wallachbeth Capital Announces Closing of bioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement

  • JERSEY CITY, N.J. , March 8, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (Nasdaq: BIAF and BIAFW) has closed a securities purchase agreement with institutional investors for the purchase and sale of 1,600,000 shares of common stock in a registered direct offering and common warrants to purchase up to 1,600,000 shares of common stock in a concurrent private placement (together with the registered direct offering) at a combined purchase price of $1.5625 per common share.
    Fri, Mar. 08, 2024

bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement

  • SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies closed a securities purchase agreement with institutional investors for gross proceeds of approximately $2.5 million.
    Fri, Mar. 08, 2024

WallachBeth Capital Announces Pricing of BioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement

  • JERSEY CITY, N.J. , March 6, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that BioAffinity Technologies (NASDAQ: BIAF; BIAFW) has entered into a securities purchase agreement with institutional investors for the purchase and sale of 1,600,000 shares of common stock in a registered direct offering and common warrants to purchase up to 1,600,000 shares of common stock in a concurrent private placement (together with the registered direct offering, the "Offering") at a combined purchase price of $1.5625 per common share.
    Wed, Mar. 06, 2024
SEC Filings
SEC Filings
Press Releases
StockPrice Release
More Headlines
News

bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement

  • SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces it has entered into a securities purchase agreement with institutional investors.
  • 03/06/2024

bioAffinity Technologies Reports Accelerating Sales Growth of CyPath® Lung

  • SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports 375% growth in sales of CyPath Lung tests in recent months.
  • 03/05/2024

bioAffinity Technologies In The News

  • SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Summary of the latest news about bioAffinity Technologies.
  • 01/30/2024

bioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer

  • SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Indian Patent Office issues patent to bioAffinity Technologies for porphyrin compounds related to targeted cancer treatment.
  • 01/23/2024

bioAffinity Technologies In the News

  • SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--A summary of latest news about bioAffinity Technologies and CyPath® Lung, its noninvasive test for the detection of early-stage lung cancer.
  • 01/08/2024

bioAffinity Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

  • ORLANDO, FL / ACCESSWIRE / January 5, 2024 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (NASDAQ:BIAF) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, January 5, at 7 p.m. Eastern Time (ET).
  • 01/05/2024

bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors

  • SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Jamie Platt, Ph.D., joins the bioAffinity Technologies Board of Directors.
  • 12/05/2023

CMS Posts Final Payment Determination for bioAffinity Technologies' CyPath® Lung Effective January 2024

  • SAN ANTONIO,--(BUSINESS WIRE)-- #BIAF--CMS has made a final determination for payment for CyPath® Lung, a noninvasive test for early-stage lung cancer, for the 2024 calendar year.
  • 11/30/2023

bioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology Post

  • SAN ANTONIO--(BUSINESS WIRE)-- #ASCB--bioAffinity Technologies VP of Research David Elzi, Ph.D., named to post with the American Society for Cell Biology.
  • 11/28/2023

bioAffinity Technologies Teams with American Cancer Society to Raise Funds for Lung Cancer Screening

  • SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies today launched a campaign in partnership with the ACS to increase lung cancer screening in Texas.
  • 11/15/2023

bioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update

  • SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports third quarter 2023 financial results and provides business update.
  • 11/14/2023

bioAffinity Technologies to Present at the 8th Annual Dawson James Small Cap Growth Conference

  • SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies presents at Dawson James Small Cap Growth Conference this week.
  • 10/10/2023

bioAffinity Technologies to Participate in the H.C. Wainwright Global Investment Conference

  • SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity President and CEO Maria Zannes will present at H.C. Wainwright Global Investment Conference Sept. 11-13.
  • 09/07/2023

bioAffinity Technologies to Report Third Quarter 2022 Financial Results

  • SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced that the Company will host a conference call and audio webcast on Monday, Nov. 14, 2022, at 8 a.m.
  • 11/08/2022

Stock Market Today: What Happened & 3 Penny Stocks To Watch Now

  • What happened in the stock market today and Penny stocks to watch this week. The post Stock Market Today: What Happened & 3 Penny Stocks To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 09/29/2022

7 Penny Sleeper Stocks to Buy Before Wall Street Wakes Up

  • Penny sleeper stocks can offer tremendous risks to investors. However, much like any other speculative investment category, it's possible that traders can still generate incredible, perhaps life changing profits.
  • 09/29/2022

Penny Stocks to Buy in a Bear Market? 3 to Watch Right Now

  • Are these penny stocks on your watchlist today? The post Penny Stocks to Buy in a Bear Market?
  • 09/29/2022

Why Is BioAffinity (BIAF) Stock Up 40% Today?

  • Early diagnosis specialist BioAffinity (NASDAQ: BIAF ) spiked 60% on Wednesday morning before paring back some gains in the afternoon to around 40% up. Investors piled into BIAF stock upon the underlying company disclosing the receipt of approximately $7.7 million in additional gross proceeds from its initial public offering (IPO).
  • 09/28/2022

What Is Going on With bioAffinity (BIAF) Stock Today?

  • Source: CI Photos / Shutterstock.com BioAffinity (NASDAQ: BIAF ) stock is rising higher on Wednesday after the cancer diagnostic company announced the publication of its research in PLOS ONE . This was published under the title Sputum analysis by flow cytometry; an effective platform to analyze the lung environment.
  • 09/14/2022

bioAffinity (BIAF) Stock Pops 100% in Red-Hot IPO

  • Well, it turns out the initial public offering ( IPO ) market isn't quite dead. The latest IPO to hit the markets today is that of bioAffinity (NASDAQ: BIAF ).
  • 09/01/2022
Unlock
BIAF Ratings Summary
BIAF Quant Ranking